This issue includes topics such as the recent AIFA approval of Avastin for off label use in Wet-AMD ...
Read moreA recent Biosimilar pricing announcement of 72% discount of an anti-tumour necrosis factor blows con...
Read moreRecent initiatives indicate EU member states are heading for potential centralised drug procurement
Read moreNICE revises biosimilars guidance to conclude that they do not believe that biosimilars are identica...
Read moreRemap Consulting presents NICE's highly specialised technology methodology to EUCOPE
Read moreUpdates on the latest news on NICE's Value Based Assessment, as well as the approval of ultra-orphan...
Read moreIf spending on Hepatitis C drugs exceeds a certain amount, drug manufacturers will be taxed
Read moreIncluding Sovaldi's $84,000 price, adaptive licence pilots from the EMA and is 2015 a turning point ...
Read moreOur quarterly newsletter shares our perspectives on the latest news, developments and thinking withi...
Read more